GeNeuro’s Causal Approach To MS Treatment Gathers Momentum

GeNeuro is making good progress on its mid-stage clinical compound that is tackling a potential cause of multiple sclerosis. An early collaboration with Servier puts the Swiss biotech on a good footing if an ongoing Phase IIb trial – due to report interim data at the end of next year – is successful.

Neurons and nervous system. 3d render of nerve cells

GeNeuro SA has hit the halfway mark of its proof-of-concept trial ahead of schedule, recently enrolling the 130th patient in the CHANGE-MS Phase IIb study of GNbAC1 in patients with relapsing-remitting multiple sclerosis (RRMS).

GNbAC1 is a monoclonal antibody designed to neutralize MSRV-Env, a human endogenous retroviral (HERV) genetic element that is silent in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By 

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

More from Therapy Areas